Member Info for Mars1

Only thing that has changed is Denstu

Loads conned to bail out at 18p at 8am by exiting shorts. Managed a small top up. Autonomous revenue from programmatic downloads won’t touch the sides as it hits the bottom line.

System proven and tested Densu on board now the game is live

Come on guys they have access to £60bn of advertising spend and a programmatic system independently tested that works no limits

Wondering whether tomorrow we will see an announcement that they intend to list on Nasdaq

Fab Phil Includes “paid promotion “ that has to be a wowser great find

https://boingboing.net/2019/09/26/watch-the-new-official-video-f.html?sfns=mo

https://boingboing.net/2019/09/26/watch-the-new-official-video-f.html?sfns=mo

Do not underestimate the importance of the 3 year extension as the increase in hit capacity in Stadia will be immense attracting brands

Investor1111 also think the value placed on 002 is grossly understated by the market

Can understand the urgency to get NXP002 into clinical trials

Will include cannabinoids adapted for purity of purpose and effectiveness the type of synthesis possible by NFX tech.
https://www.visualcapitalist.com/premium-cannabis-the-next-big-wave/

Yatai have just set up in Canada for cannabinoids they may want some of the action from Ebers

From Plums AGM1 summary referring to the Chinese payment;
“ however he indicated that there were more commercial discussions surrounding this, the payment is tied to other potential commercial arrangements. ”
It would take something important for the Chairman of Newsummit to visit London in person so the additional commercial discussions are interesting because it could be related to any of the portfolio.

DaveW58 consumer products do not require testing as they are natural products of course medical grade pharma products will as you say. Royalties are there to pick up early revenue from the consumer therapeutic market.

Sorry forgot the attachment
https://www.google.co.uk/amp/s/247wallst.com/consumer-products/2019/01/02/10-largest-marijuana-companies-3/amp/

Top ten cannabis companies in the US are attached. It includes GW Pharma that has Epidialex and is valued at US3.15 bn. Not inconsequential values and given the widespread potential use of cannabinoids probably more valuable than NXP002.

Any comments made re ROW contracts for NXP1?

Plums really good post so far

At some point the drugs ready for commercialisation and those on the way will provide evidence of value with further payments.
https://xconomy.com/boston/2018/10/18/abbvie-commits-100m-to-morphic-in-fibrosis-drug-rd-alliance/